ID: ALA3658966
Chembl Id: CHEMBL3658966
PubChem CID: 67432866
Max Phase: Preclinical
Molecular Formula: C20H18FN7O5
Molecular Weight: 455.41
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: C[C@@H]1CN2c3c(cc4c(-n5cncn5)noc4c3F)CC3(C(=O)NC(=O)NC3=O)[C@H]2[C@H](C)O1
Standard InChI: InChI=1S/C20H18FN7O5/c1-8-5-27-13-10(3-11-14(12(13)21)33-26-16(11)28-7-22-6-23-28)4-20(15(27)9(2)32-8)17(29)24-19(31)25-18(20)30/h3,6-9,15H,4-5H2,1-2H3,(H2,24,25,29,30,31)/t8-,9+,15-/m1/s1
Standard InChI Key: XRTAULGTMMIAID-CEFVDNRUSA-N
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
| Molecular Weight: 455.41 | Molecular Weight (Monoisotopic): 455.1353 | AlogP: 0.44 | #Rotatable Bonds: 1 |
| Polar Surface Area: 144.48 | Molecular Species: NEUTRAL | HBA: 10 | HBD: 2 |
| #RO5 Violations: ┄ | HBA (Lipinski): 12 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 1 |
| CX Acidic pKa: 7.31 | CX Basic pKa: 1.22 | CX LogP: 0.95 | CX LogD: 0.61 |
| Aromatic Rings: 3 | Heavy Atoms: 33 | QED Weighted: 0.50 | Np Likeness Score: -0.71 |
| 1. (2015) Chemical compounds 542, |
| 2. Basarab GS,Doig P,Eyermann CJ,Galullo V,Kern G,Kimzey A,Kutschke A,Morningstar M,Schuck V,Vishwanathan K,Zhou F,Gowravaram M,Hauck S. (2020) Antibacterial Spiropyrimidinetriones with N-Linked Azole Substituents on a Benzisoxazole Scaffold Targeting DNA Gyrase., 63 (20): [PMID:32914979] [10.1021/acs.jmedchem.0c01100] |
| 3. Govender P, Müller R, Singh K, Reddy V, Eyermann CJ, Fienberg S, Ghorpade SR, Koekemoer L, Myrick A, Schnappinger D, Engelhart C, Meshanni J, Byl JAW, Osheroff N, Singh V, Chibale K, Basarab GS.. (2022) Spiropyrimidinetrione DNA Gyrase Inhibitors with Potent and Selective Antituberculosis Activity., 65 (9.0): [PMID:35500229] [10.1021/acs.jmedchem.2c00266] |
Source(2):
